What is the most exciting ASX small-cap share of 2020?

Here's a closer look at one ASX small-cap share I think has the potential to grow materially in the future and bring investors large returns.

| More on:
Goldfish leaping out of its small bowl into a larger bowl

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX is littered with small-cap shares all vying to be global leaders in their fields. These innovative start-up companies seek to pursue untapped market opportunities that could one day bring them to stardom like industry giants CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH).

The key is to identify which ASX small-cap shares have the potential to grow materially in the future and bring investors large returns.

I believe shares within the healthcare sector are a good place to start. People view healthcare as a non-discretionary spend, including in times of economic downturn.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is one such ASX small-cap share that has a promising outlook ahead. The company is founder-led and is on the cusp of commercialising its patented hero drug.

Below, I put a microscope to Paradigm and explore whether this biopharma share is a buy.

What does Paradigm do?

This late-stage company is focused on repurposing the drug pentosane polysulphate sodium (PPS) for the treatment of musculoskeletal disorders in humans with degenerative disease driven by injury, virus infection, ageing or genetic predisposition.

Paradigm's leading drug candidate, Zilosul, is used to treat osteoarthrosis (OA), a progressive disease that affects over 240 million globally. The injectable PPS treatment showed its efficacy in patients with OA, resulting in pain reduction, improved joint function, and the prevention of cartilage damaging joints.

Paradigm's update and addressable market

In September last year, the US Food and Drug Administration (FDA) approved the 'Expanded Access Program' whereby Paradigm was able to treat 10 former NFL players who suffer from OA with Zilosul. Trials commenced in February and as of late July, the company revealed that patients reported a 65% mean pain reduction after 12 weeks.

Paradigm confirmed that its primary and secondary Phase III trials are expected to run until late 2022 where results will be announced. However, prior to the completion of these trials, the company will seek provisional approval in Australia with the Therapeutic Goods Administration (TGA).

The potential revenue in the near term is estimated to be $1.5 billion per annum. And should the FDA approve Paradigm's new drug application following its Phase III results, the addressable market in the US alone is US$9 billion per annum. To put that into perspective, Paradigm's market cap at the time of writing is $637 million.

Paradigm's financials

The company released its latest activities statement for the quarter ending 30 June. Paradigm reported a cash on hand balance of $104.6 million, a net operating cash flow of $4.7 million and no debt.

With a strong balance sheet, the biopharma company should be able to fund its operations through 2022 without additional capital raising or loans from creditors.

Should you invest in this ASX small-cap share?

Over the past 12 months, the Paradigm share price has rocketed higher to $2.81, up 102% (at the time of writing).

If the company's drug Zilosul is approved by both the TGA and FDA to treat sufferers for OA, I believe Paradigm will generate multiple returns for years to come. The potential recurring revenue is enormous should the company penetrate even as little as 10% of the OA market.

In light of this, I would rate Paradigm as a buy for the more risk tolerant investor looking to invest in ASX small-cap shares.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cheap Shares

a smiling picture of legendary US investment guru Warren Buffett.
Cheap Shares

I'm listening to Warren Buffett and buying cheap ASX shares

Attractively valued ASX shares are a great call right now, in my view.

Read more »

Dog with a shoe in its mouth.
Cheap Shares

I think these 2 cheap ASX shares are buys for value investors

These businesses could be too cheap to ignore.

Read more »

An Australian farmer wearing a beaten-up akubra hat and work shirt leans on a fence with livestock in the background and a blue sky above.
Cheap Shares

Why I think these 2 ASX 300 shares are steals

These ASX shares have a lot of potential, in my view.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Cheap Shares

2 cheap ASX 200 shares that look too good to ignore today

Cheap shares are hard, but not impossible, to find right now.

Read more »

A cool dude looks back at the camera while ziplining above the treetops.
Cheap Shares

2 great ASX shares to buy in July: experts

These companies have a lot going for them. Here’s why.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Cheap Shares

In an expensive market, 2 ASX 200 companies too cheap to ignore

These two businesses seem far too cheap for what could happen next.

Read more »

a man and a woman kneel in a boxing ring with exaggerated make-up injuries, posing in humorous stance with the woman leaning back on her knees and the man leaning against her bright pink boxing glove as he gasps for air.
Cheap Shares

Is it time to buy these 2 beaten-up ASX shares in 2025?

These ASX shares could be great buys right now.

Read more »

Man smiling at a laptop because of a rising share price.
Cheap Shares

Why this fund manager bought this ASX 300 share for bigger returns

A fund manager thinks good things can happen with this rising ASX share.

Read more »